The U.S. Food and Drug Administration approved Afluria, an additional seasonal influenza vaccine for the immunization of people ages 18 and older.Afluria is intended to protect adults from influenza type A and type B flu viruses. Influenza is a contagious respiratory illness that can cause annual epidemics. The approval of Afluria, manufactured by CSL Limited of Parkville, Australia, brings the number of seasonal influenza manufacturers licensed for the U.S.
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Although many people “felt robbed” by the announcement last week that Merck’s trial of an experimental HIV vaccine had been halted, it would be “worse [to] allow the news to slow progress” toward development of future HIV vaccines, Seth Berkley, president and CEO of the International AIDS Vaccine Initiative, writes in a
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
As policy makers debate what levels of ozone in the air are safe for humans to breathe, studies in mice are revealing that the inhaled pollutant impairs the body’s first line of defense, making it more susceptible to subsequent foreign invaders, such as bacteria.
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
A new study examined the possible associations between occupation and the risk of dying from systemic autoimmune diseases and found that occupational exposures in farming and industry may be linked to higher death rates from these diseases.More than 8 million Americans suffer from autoimmune diseases, in which the immune system attacks the body’s own tissues and several occupational exposures have been linked to systemic autoimmune diseases, which affect multiple organs.
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
Researchers at the Partners AIDS Research Center at Massachusetts General Hospital (PARC-MGH) may have discovered a second molecular “switch” responsible for turning off the immune system’s response against HIV. Last year members of the same team identified a molecule called PD-1 that suppresses the activity of HIV-specific CD8 T cells that should destroy virus-infected cells.
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
Read the full article...
